Diagnosis and Management of Common Sleep Disorders – An Overview for the Psychiatrist

Diagnosis and Management of Common Sleep Disorders – An Overview for the Psychiatrist

Capasso Robson, Mignot Emmanuel

Emmanuel Mignot et al.

European Psychiatric Review 2008;1(1):44-50

download article

| More
dots

“Sleep is the golden chain that ties health and our bodies together.” Thomas Dekker

Untreated sleep disorders such as sleep apnoea, restless legs syndrome (RLS) and narcolepsy are common and often undiagnosed. They have significant effects on quality of life and can even lead to death, for example in the context of an accident caused by tiredness while driving. Furthermore, these disorders can cause symptoms that may be confused with neuropsychiatric conditions such as depression or schizophrenia or that can contribute to treatment resistance. A number of studies have shown associations between sleep and genuine neuropsychiatric disorders.

The Basic Neurobiology of Sleep
Sleep is not a passive state. The neural substrates underlying sleep states include sleep- and wake-on neuronal networks. Wake-on-promoting systems are typically brainstem and hypothalamic systems that project to the cortex and or the thalamus, which then activates the cortex. These include cholinergic ascending systems (pedunculopontine and laterodorsal tegmental areas and basal forebrain), adrenergic locus coeruleus, serotonergic raphe nuclei, hypocretin-containing lateral hypothalamic systems and histamine-containing tuberomammillary hypothalamic nuclei. General brain activation ensues, with high glutamate release and electroencephalography (EEG) desynchronisation and consciousness. Wakefulness is the co-ordinated expression of many behaviours that are constantly changing in response to variations in the external and internal milieu. Most likely, each arousal system is particularly active under specific circumstances, and there is an intense interaction among them.1,2 Dopaminergic cell groups of the substantia nigra (SN) and ventral tegmental area (VTA), for example, do not seem to significantly increase overall neuronal activity in wakefulness, but are certainly activated by specific behaviours in wakefulness and are involved in the wakepromoting effects of most stimulants, such as amphetamines, methylphenidate and modafinil.

A smaller number of systems are sleep-active in the brain: during nonrapid eye movement (NREM) sleep, most of the brain activity is decreased and the EEG is desynchronised, characterised by the appearance of slow wave activity. Major sleep-promoting centres include a group of anterior gamma-aminobutyric acid (GABA)-ergic hypothalamic and basal forebrain sleep-on networks, including the ventrolateral preoptic (VLPO) and median preoptic (MnPO) nucleus of the hypothalamus.3 These systems strongly inhibit the wake-active systems mentioned above. Of final interest is REM sleep, a paradox as the brain is generally active (most notably the cortex, with a wave-like desynchronised EEG and associated dreaming) while REM and muscle paralysis (atonia) occur. In REM sleep, cholinergic systems and many sleep-on systems are active, but monoaminergic systems are turned off.4–6 Most antidepressants are strong REM sleep suppressants. Sleep and wake tendencies can be seen as the sum of two processes: homeostatic and circadian.

To view full article click here

References:
  1. España RA, Scammell TE, Sleep neurobiology for the clinician, Sleep, 2004;27(4):811–20.
  2. Saper CB, Chou TC, Scammell TE, The sleep switch: hypothalamic control of sleep and wakefulness, Trends Neurosci, 2001;24:726–31.
  3. Uschakov A, Gong H, McGinty D, Szymusiak R, Neuroscience, 2007;150(1):104–20.
  4. Lu J, Greco MA, Sleep circuitry and the hypnotic mechanism of GABAA drugs, J Clin Sleep Medicine, 2006;2(2):S19–26.
  5. Borbely AA, Achermann P, Concepts and models of sleep regulation: an overview, J Sleep Res, 1992;1:63–79.
  6. Wurts SW, Edgar DM, Circadian and homeostatic control of REM sleep: promotion of REM tendency by the supra-chiasmatic nucleus, Neuroscience, 2000;20:4300–10.
  7. Moore RY, Suprachiasmatic nucleus in sleep–wake regulation, Sleep Med, 2007;8(Suppl. 3):27–33.
  8. Buysse DJ, Definition, Diagnosis, Classification and Etiology of Chronic Insomnia, J Clin Sleep Medicine, 2005;1(4)452–3.
  9. NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults, NIH State-of-the-Science Conference Statement, 2005.
  10. Tsuno N, Besset A, Ritchie K, Sleep and depression, J Clin Psychiatry, 2005;66(10):1254–69.
  11. Fava M, McCall WV, Krystal A, et al., Eszopiclone co-administered with fluoxetine in patients with insomnia co-existing with major depressive disorder, Biol Psychiatry, 2006;59(11):1052–60.
  12. Papadimitriou GN, Linkowski P, Sleep disturbance in anxiety disorders, Int Rev Psychiatry, 2005;17(4):229–36.
  13. Morin CM, Combined therapeutics for insomnia: should our first approach be behavioral or pharmacological?, Sleep Med, 2006;7(Suppl. 1):S15–19.
  14. Morin CM, Cognitive-Behavioral Approaches to the Treatment of Insomnia, J Clin Psychiatry, 2004;65(Suppl. 16):33–40.
  15. Sack RL, Auckley D, Auger RR, et al., American Academy of Sleep Medicine. Circadian rhythm sleep disorders, Sleep, 2007;30(11): 1484–1501.
  16. Westrin A, Lam RW, Seasonal affective disorder: a clinical update, Ann Clin Psychiatry, 2007;19(4):239–46.
  17. Lewy AJ, Emens JS, Lefler BJ, et al., Melatonin entrains free-running blind people according to a physiological dose–response curve, Chronobiol Int, 2005;22(6):1093–1106.
  18. Silber M, Chronic Insomnia, New Eng J Med, 2005;353:803–10.
  19. Neubauer DN, Pharmacologic approaches for the treatment of chronic insomnia, Clin Cornerstone, 2003;5:16–19.
  20. Neubauer DN, PDR Clinical Handbook: Insomnia with Clinical Strategies, New York: Thompson, 2004.
  21. Holbrook AM, Crowther R, Lotter A, et al., Canadian Medical Association Journal, 2000;162(2):225–33.
  22. Devi V, Shankar PK, Ramelteon: A melatonin receptor agonist for insomnia, J Postgrad Med, 2008;54(1):45–8.
  23. Karatas M, Restless legs syndrome and periodic limb movements during sleep, Neurologist, 2007;13(5):294–301.
  24. Littner MR, Kushida C, Anderson WM, et al., Practice Parameters for the Dopaminergic Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder, An American Academy of Sleep Medicine Report, Sleep, 2004;27(3):557–9.
  25. International Classification of Sleep Disorders, Diagnostic and coding manual, 2nd edn, American Sleep Disorders Association, Westchester, 2006.
  26. Ford DE, Kamerow DB, Epidemiological study of sleep disturbances and psychiatric disorders: An opportunity for prevention?, JAMA, 1989;262:1479–84.
  27. Amercian Psychiatric Association, Diagnostic Criteria from Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), Washington DC, 2000.
  28. Tsuno N, Besset A, Ritchie K, Sleep and Depression, J Clin Psychiatry, 2005;66(10):1254–69.
  29. Nofzinger EA, Thase ME, Reynolds CF, et al., Hypersomnia in bipolar depression, Am J Psychiatry, 1991;148(9):1177–81.
  30. Guilleminault C, Tilkian A, Dement WC, The sleep apnea syndromes, Annu Rev Med, 1976;27:465–84.
  31. Young T, Palta M, Dempsey J, et al., The occurrence of sleep-disordered breathing among middle-aged adults, N Engl J Med, 1993;328:1230–35.
  32. Guilleminault C, Kirisoglu C, Poyares D, et al., Upper airway resistance syndrome: a long-term outcome study, J Psychiatr Res, 2006;40(3):273–9.
  33. Patel SR, White DP, Malhotra A, et al., Continuous positive airway pressure therapy for treating sleepiness in a diverse population with obstructive sleep apnea: results of a meta-analysis, Arch Intern Med, 2003;163:565–71.
  34. Morisson F, Decary A, Petit D, et al., Daytime sleepiness and EEG spectral analysis in apneic patients before and after treatment with continuous positive airway pressure, Chest, 2001;119:45–52.
  35. Riley RW, Powell NB, Guilleminault C, Otolaryngol Head Neck Surg. 1993;108(2):117–25.
  36. Leibowitz SM, Brooks SN, Black JE, Excessive Daytime Sleepiness: Considerations for the Psychiatrist Psychiatric Clinics of North America, 2006;29:921–45.
  37. Mignot E, Lammers GJ, Ripley B, et al., The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias, Arch Neurol, 2002;59:1553–62.
  38. Peyron C, Faraco J, Rogers W, A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains, Nat Med, 2000;6:991–7.
  39. Overeem S, Mignot E, van Dijk JG, et al., clinical features, new pathophysiologic insights and future perspectives, J Clin Neurophysiol, 2001;18:78–105.
  40. Scammell TE, The neurobiology, diagnosis and treatment of narcolepsy, Ann Neurol, 2003;53:154–66.
  41. Anic-Labat S, Guilleminault C, Kraemer HC, et al., Validation of a cataplexy questionnaire in 983 sleep-disorder patients, Sleep, 1999;22:77–87.
  42. Dauvilliers Y, Arnulf I, Mignot E, Narcolepsy with cataplexy Lancet, 2007;369:499–511.
  43. Broughton R, Ghanem Q, Hishikawa Y, et al., Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared with matched controls, Can J Neurol Sci, 1981;8:299–304.
  44. Beusterien KM, Rogers AE, Walsleben JA, Health-related quality of life effects of modafinil for treatment of narcolepsy, Sleep, 1999;22:757–65.
  45. Roth B, Nevsimalova S, Depression in narcolepsy and hypersommia, Arch Neurol Neurochir Psychiatr, 1975;116: 291–300.
  46. Mignot E, Lin L, Rogers W, et al., Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups, Am J Hum Genet, 2001;68:686–99.
  47. Siebold, Hansen BE, Wyer JR, et al., Crystal structure of HLADQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy, Proc Natl Acad Sci U S A, 2004;10.
  48. Billiard M, Modafinil: pharmacology and therapeutic perspectives, Rev Neurol, 2003;159:122–5.
  49. Mignot E, Nishino S, Guilleminault C, Dement WC, Modafinil binds to the dopamine uptake carrier site with low affinity, Sleep, 1994;17:436–7.
  50. Mitler MM, Shafor R, Hajdukovich R, et al., Treatment of narcolepsy: objective studies on methylphenidate, pemoline and protriptyline, Sleep, 1986;9:260–64.
  51. Auger RR, Goodman SH, Silber MH, et al., Risks of high-dose stimulants in the treatment of disorders of excessive somnolence, Sleep, 2005;28:667–72.
  52. N Langdon, J Shindler, JD Parkes, Bandak S, Fluoxetine in the treatment of cataplexy, Sleep, 1986;9:371–3.
  53. M Smith, J Parkes, Dahlitz M, Venlafaxine in the treatment of the narcoleptic syndrome, J Sleep Res, 1996;5:217.
  54. TE Scammell, The neurobiology, diagnosis and treatment of narcolepsy, Ann Neurol, 2003;53:154–66.
  55. J Black, Houghton W, Xyrem International Study Group, Sodium oxybate improves excessive daytime sleepiness in narcolepsy, Sleep, 2006;29:939–46.
  56. US Xyrem Multicenter Study group, A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy, Sleep, 2002;25:42–9.
  57. Arnulf I, Zeitzer JM, File J, et al., Kleine-Levin syndrome: a systematic review of 186 cases in the literature, Brain, 2005;128:2763–76.
  58. Iranzo A, Molinuevo JL, Santamaría J, et al., REM sleep behavior disorder as an early marker for a neurodegenerative disorder: a descriptive study, Lancet Neurol, 2006;5(7):572–7.

Copyright® 2012 Touch Group PLC. All rights reserved.
Touch Neurology is for informational purposes and should not be considered medical advice, diagnosis or treatment recommendations.